Marvell Technology, Inc. Accrued Royalties (Current) increased by 26.0% to $25.20M in Q3 2025 compared to the prior quarter. Over 2 years (FY 2021 to FY 2025), Accrued Royalties (Current) shows relatively stable performance with a -4.2% CAGR.
An increase generally correlates with higher sales of licensed products, reflecting successful commercialization efforts.
The liability representing royalty payments that have been earned by third parties based on product sales but have not y...
Specific to companies with licensed technology or intellectual property, common in the biotech sector.
accrued_royalties_current| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.34M | $20.51M | $15.92M | $17.40M | $18.80M | $22.00M | $15.90M | $11.70M | $19.10M | $20.00M | $25.20M |
| QoQ Change | — | +25.6% | -22.4% | +9.3% | +8.0% | +17.0% | -27.7% | -26.4% | +63.2% | +4.7% | +26.0% |
| YoY Change | — | — | — | — | +15.1% | +7.2% | -0.1% | — | — | — | — |